Western Health - Sunshine Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soroka, Steven
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
Pedagogos, Eugenia
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Recruiting
2
100
US, RoW
ANG-3070, Placebo
Angion Biomedica Corp, Angion Biomedica Corp.
Glomerular Disease, Proteinuria
07/23
08/23
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26

Download Options